Aurinia Pharmaceuticals Inc [AUPH] stock is trading at $14.61, up 4.73%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AUPH shares have gain 10.93% over the last week, with a monthly amount glided 25.73%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] stock has seen the most recent analyst activity on November 07, 2025, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $21 for it. Previously, RBC Capital Mkts downgraded its rating to Sector Perform on November 05, 2025, and kept the price target unchanged to $15. Oppenheimer downgraded its rating to a Perform. Oppenheimer upgraded its rating to Outperform for this stock on December 10, 2021, and downed its price target to $31. In a note dated October 28, 2021, Oppenheimer downgraded an Perform rating on this stock but restated the target price of $32.
Aurinia Pharmaceuticals Inc [AUPH] stock has fluctuated between $6.55 and $16.20 over the past year. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] shares were valued at $14.61 at the most recent close of the market. An investor can expect a potential return of 2.67% based on the average AUPH price forecast.
Analyzing the AUPH fundamentals
Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] reported sales of 265.81M for the trailing twelve months, which represents a growth of 8.41%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.3%, and Net Profit Margin reading is 0.29%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.22 and Total Capital is 0.16. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.32 points at the first support level, and at 14.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.08, and for the 2nd resistance point, it is at 15.56.
Ratios To Look Out For
For context, Aurinia Pharmaceuticals Inc’s Current Ratio is 5.76. Further, the Quick Ratio stands at 5.17, while the Cash Ratio is 0.96. Considering the valuation of this stock, the price to sales ratio is 7.25, the price to book ratio is 5.27 and price to earnings (TTM) ratio is 26.04.
Transactions by insiders
Recent insider trading involved TANG KEVIN, Director, that happened on Aug 01 ’25 when 1.0 million shares were purchased. Director, TANG KEVIN completed a deal on Aug 05 ’25 to buy 0.2 million shares. Meanwhile, Director TANG KEVIN bought 100000.0 shares on Aug 04 ’25.
